There is provided a compound of Formula I
1
wherein each T is independently selected from H, hydrocarbyl, —F—R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which is m; D, E and F are each independently of each other an optional linker group, wherein when Z is nitrogen E is other than CH
2
and C═O; P, Q and R are independently of each other a ring system; and at least Q comprises a sulphamate group.
[EN] 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS<br/>[FR] DERIVES 1,2,4-TRIAZOLE CONTENANT UN GROUPE SULFAMATE EN TANT QU'INHIBITEURS D'AROMATASE
申请人:STERIX LTD
公开号:WO2003045925A1
公开(公告)日:2003-06-05
There is provided a compound of Formula (I), wherein each T is independently selected from H, hydrocarbyl, -F-R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which is m; D, E and F are each independently of each other an optional linker group, wherein when Z is nitrogen E is other than CH2 and C=O; P, Q and R are independently of each other a ring system; and at least Q comprises a sulphamate group.
作者:L. W. Lawrence Woo、Christian Bubert、Oliver B. Sutcliffe、Andrew Smith、Surinder K. Chander、Mary F. Mahon、Atul Purohit、Michael J. Reed、Barry V. L. Potter
DOI:10.1021/jm061462b
日期:2007.7.1
By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM), and 14, (IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM). X-ray crystallography of 5, and docking studies of selected compounds into an aromatase homology model and the steroid sulfatase crystal structure are presented. Both 5 and 14 inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose. Almost complete dual inhibition is observed for 5 but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h. DASI 5 did not inhibit aldosterone synthesis. The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.
1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS